skip to Main Content

Recorded Webinar with Dr. Kevin Burns: Cord Blood Endothelial Colony Forming Cell-Derived Exosomes in Acute Kidney Injury

Recorded on Wednesday, September 20th, 2017

Share the Science

Watch the recorded webinar to hear Dr. Kevin Burns, professor of medicine in the Division of Nephrology at the University of Ottawa and senior scientist at the Ottawa Hospital Research Institute, discuss the clinical significance of acute kidney injury and using exosomes from cord blood-derived endothelial colony forming cells as potential treatment.

Webinar Summary

Acute kidney injury (AKI) is a serious clinical condition characterized by the abrupt loss of kidney function, often precipitated by hypotension, sepsis, or nephrotoxic agents. AKI is highly prevalent in hospitalized patients (1%-5%), has a high mortality rate, and often leads to chronic kidney disease in those who recover kidney function. Despite many decades of research, however, no treatments have been shown to be effective in restoring kidney function after AKI, and current management consists of supportive care with dialysis as needed.

During this webinar, Dr. Burns presents research findings from his laboratory on the reparative properties of extracellular vesicles (exosomes) isolated from human cord blood-derived endothelial colony forming cells (ECFCs) in experimental AKI. When infused into mice with ischemia/reperfusion AKI, ECFC exosomes protect against loss of kidney function, prevent inflammatory cell infiltration into the kidneys, and inhibit apoptotic responses. Using next-generation sequencing of small RNAs, his lab found that ECFC exosomes are highly enriched in microRNA-486-5p, which targets the pro-apoptotic factor PTEN. Data from his lab supports the notion that infused exosomes transfer microRNA-486-5p to injured kidney endothelial cells after ischemia/reperfusion AKI, leading to inhibition of PTEN and subsequent activation of the pro-survival Akt pathway. He also presents data indicating that infused ECFC exosomes selectively home to the injured kidneys after AKI. This webinar presents information suggesting that ECFC-derived exosomes hold promise as potential therapeutic agents in humans with AKI.

You will learn about the:

  • Clinical significance of acute kidney injury and the rationale for the use of cellular therapy
  • Effects of administration of ECFCs in experimental ischemia/reperfusion AKI
  • Potential role of ECFC-derived exosomes in mediating therapeutic responses in AKI in vivo and in cell culture models
  • Potential role of microRNA transfer in the kidney in mediating the protective effects of exosome treatment

Kevin D. Burns MD, CM, FRCP(C), discusses acute kidney injury, his clinical research, and data supporting the use of cord blood-derived endothelial colony forming cells as potential treatment.

Speaker Bio

Kevin D. Burns MD, CM, FRCP(C) is a professor of medicine in the division of Nephrology at the Department of Medicine of the Ottawa Hospital and University of Ottawa. He is senior scientist and director of the Kidney Research Centre of the Ottawa Hospital Research Institute and is cross-appointed to the Department of Cellular and Molecular Medicine. Dr. Burns’ research has focused on the function and regulation of the intrarenal renin-angiotensin system in diabetic nephropathy and hypertension and the pathogenesis and treatment of acute kidney injury.

He received his BSc and MD degrees from McGill University and completed internal medicine residency and clinical nephrology fellowship training at the University of Ottawa. Dr. Burns also undertook basic science research training at Vanderbilt University Medical Center. His laboratory has been supported by funds from the Canadian Institutes of Health Research (CIHR), the Kidney Foundation of Canada (KFOC), and the Canada Foundation for Innovation/Ontario Innovation Trust.

Dr. Burns is past president of the Canadian Society of Nephrology (CSN) and is chair of the steering committee for the KRESCENT Program, a national kidney research training program launched by the CSN, the KFOC, and the CIHR. In 2010, Dr. Burns received the Medal for Research Excellence from the KFOC in recognition of his contributions to kidney research in Canada


Mediware and Save the Cord Foundation are proud to bring you this exclusive speaker series to discuss the topics you and your peers are most interested in. Join us as we feature your colleagues to discuss their latest research, opinions on industry news, and so much more. We look forward to having you on board for this exciting series!

Back to top